Full history for every metric is available with a Kvantra account
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 1 | 1 | 1 | 1 | 1 | 6 | 12 | 12 |
| Operating profit | $m | -21 | -24 | ||||||
| Net profit | $m | -14 | -18 | -14 | -9 | -12 | -41 | -157 | - |
| EPS reported | $ | -1.85 | -30.32 | ||||||
| Operating cashflow per share | $ | -0.75 | -0.34 | ||||||
| Capex per share | $ | 2.03 | 0.00 | ||||||
| FCF per share | $ | -2.78 | -0.34 | ||||||
| Free cash flow | $m | -61 | -27 | ||||||
| Net debt | $m | -7 | -4 | ||||||
| Book value equity | $m | 301 | 166 | ||||||
| Book value per share | $ | 13.65 | 2.12 | ||||||
| Number of shares | m | 22.05 | 78.25 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 0.21 | 0.93 | ||||||
| P/S LTM | x | 10.59 | 12.77 | ||||||
| P/FCF LTM | x | -1.04 | -5.72 | ||||||
| EV/EBITDA LTM | x | -1.43 | -1.11 | ||||||
| EV/Sales LTM | x | 9.38 | 12.47 | ||||||
| Earnings Yield LTM | % | -64.17% | -76.13% | ||||||
| FCF Yield | % | -96.19% | -17.48% | ||||||
| Quality | |||||||||
| ROE | % | -13.59% | -122.85% | ||||||
| ROIC | % | -7.02% | -13.92% | ||||||
| Operating margin | % | -351.02% | -200.47% | ||||||
| Gross margin | % | 91.69% | 95.53% | ||||||
| FCF/Sales | % | -1018.7% | -223.19% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +1057.1% | +3992.2% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | 0.00% | 0.00% | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | - | - | ||||||
| Net Debt/EBITDA | x | 0.18 | 0.03 | ||||||
| EBIT/Net interest | x | -33.26 | -355.90 | ||||||
| Net debt/market cap | % | -11.43% | -2.37% | ||||||
| Net debt/Equity | x | -0.02 | -0.02 | ||||||
| Gross debt/equity | x | 0.00 | 0.00 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Solana Co. is a medical device firm specializing in neurotechnology, dedicated to improving neurological wellness. The company's strategy involves developing, licensing, and acquiring innovative, non-invasive platform technologies. These technologies are designed to enhance the brain's intrinsic capacity for self-healing and mitigate the effects of neurological diseases or trauma. A prime example of their work is the development of an investigational portable neuromodulation stimulator. This device uniquely delivers neurostimulation through the tongue. Clinical studies have indicated that this approach significantly enhances the efficacy of physical exercises for individuals experiencing neurological symptoms stemming from conditions like disease or trauma, including mild-to-moderate traumatic brain injury. Established on March 13, 2014, Solana Co. maintains its headquarters in Newtown, Pennsylvania.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Solana Co. is a medical device firm specializing in neurotechnology, dedicated to improving neurological wellness. The company's strategy involves developing, licensing, and acquiring innovative, non-invasive platform technologies. These technologies are designed to enhance the brain's intrinsic capacity for self-healing and mitigate the effects of neurological diseases or trauma. A prime example of their work is the development of an investigational portable neuromodulation stimulator. This device uniquely delivers neurostimulation through the tongue. Clinical studies have indicated that this approach significantly enhances the efficacy of physical exercises for individuals experiencing neurological symptoms stemming from conditions like disease or trauma, including mild-to-moderate traumatic brain injury. Established on March 13, 2014, Solana Co. maintains its headquarters in Newtown, Pennsylvania.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free